Bratisl Lek Listy. 2021;122(10):744-747. doi: 10.4149/BLL_2021_119.
Vitamin D has anti-inflammatory and immunomodulatory effects via the downregulation of pro-inflammatory cytokines. We aimed to demonstrate the effect of vitamin D levels on survival in COVID-19 patients.
207 COVID-19 patients were included in the study. Serum vitamin D levels were measured, and patients with levels <20 ng/ml or 21 to 30 ng received a single 300.000 IU dose of vitamin D.
Of 207 patients, 37 received vitamin D, while 170 did not. Demographic, radiologic and mean laboratory values were similar between the groups. The mean plasma vitamin D level without vitamin D support (n=170) was 50.82±16.12 ng/ml (30.28-81.35) vs. 16.98±6.2 ng/ml (4.20-28.30) in vitamin D group. The most remarkable finding were the mortality rates; while only 1 patient (2.7 %) died in the vitamin D group, 24 patients (14.1 %) died in no vitamin D supplementation group (p=0.038).
Although a few retrospective studies put forth a relation between vitamin D deficiency and COVID-19 course severity there is still paucity of data about the efficacy of vitamin supplementations in COVID-19 patients. A single 300.000 IU dose of vitamin D seems to represent a useful, practical, and safe adjunctive approach for the treatment or prevention of COVID-19 (Tab. 1, Fig. 1, Ref. 30).
维生素 D 通过下调促炎细胞因子具有抗炎和免疫调节作用。我们旨在证明维生素 D 水平对 COVID-19 患者生存的影响。
本研究纳入了 207 例 COVID-19 患者。测量了血清维生素 D 水平，维生素 D 水平<20ng/ml 或 21-30ng 的患者单次给予 300000IU 维生素 D 剂量。
207 例患者中，37 例接受了维生素 D 治疗，170 例未接受。两组间的人口统计学、影像学和平均实验室值相似。无维生素 D 支持的患者（n=170）的平均血浆维生素 D 水平为 50.82±16.12ng/ml（30.28-81.35），而维生素 D 组为 16.98±6.2ng/ml（4.20-28.30）。最显著的发现是死亡率；虽然维生素 D 组只有 1 例（2.7%）死亡，但在未补充维生素 D 的组中有 24 例（14.1%）死亡（p=0.038）。
尽管一些回顾性研究提出了维生素 D 缺乏与 COVID-19 病程严重程度之间的关系，但关于 COVID-19 患者维生素补充的疗效的数据仍然很少。单次 300000IU 维生素 D 剂量似乎是一种有用、实用且安全的 COVID-19 治疗或预防辅助方法（表 1，图 1，参考文献 30）。
